Global Economic Outlook and Capital Availability: The anticipated downgrade of global growth forecasts due to geopolitical conflicts may tighten capital markets, reducing investor appetite for high-risk assets like clinical-stage biotech stocks and making it more challenging for ACTU to secure vital funding for R&D and clinical trials.

Market Sentiment Towards High-Growth/Biotech Stocks: Increased uncertainty from global geopolitical and economic concerns tends to drive investors towards safer assets, potentially leading to greater volatility and downward pressure on ACTU's stock price, irrespective of its internal clinical progress.

US Economic Strength as a Stabilizing Factor: A robust US economy, evidenced by strong job growth and low unemployment, can provide a stabilizing effect on the broader equity market, potentially cushioning some negative impacts from global headwinds and maintaining a baseline of investor confidence in US-listed companies, including the biotech sector.